The Role of Aflibercept (Eylea) Intravitreal Injection in Treatment of Resistant or CNV Complicated CSR (Central Serous Retinopathy)

Authors

  • Dr. Nawres Kadhim Almudhafar MD, Ophthalmologist, Basra Health Directorate, Ministry of Health, Basra, Iraq
  • Dr. Mustafa Abdulhasan Alsuraih MD, Ophthalmologist, Basra Health Directorate, Ministry of Health, Basra, Iraq
  • Dr. Hamid M. Altaha MD, Lecturer of Ophthalmology, Medical College, Basrah University
  • Dr. Falah Abdulhassan Alsiraih Diploma Community Medicine, Basra Health Directorate, Ministry of health, Basra, Iraq
  • Dr. Khalid Khalaf Ali Alkanan MD, Ophthalmologist, Basra Health Directorate, Ministry of health, Basra, Iraq

DOI:

https://doi.org/10.70135/seejph.vi.1504

Keywords:

Aflibercept (Eylea), Treatment of Resistant or CNV Complicated CSR

Abstract

Purpose to evaluate the benefit and side effects of intravitreal Aflibercept (Eylea) injection in the treatment of cases that are resistant to previous treatment choices or complicated with  CNV due to central serous retinopathy [CSR]

Methods

It is retrospective study on 72 patients with diagnosed to have CSR and follow up for 12-18 months we can consider that there is complete resolution if subretinal fluid disappeare for 3 months from last intravitreal injection of Eylea

We planned this research to demonstrate the efficiency of aflibercept intravitreal injection in the treatment of cases that resistant to treatment or complicated with CNV secondary to CSR.

Downloads

Published

2024-10-04

How to Cite

Almudhafar, D. N. K., Alsuraih, D. M. A., Altaha, D. H. M., Alsiraih, D. F. A., & Alkanan, D. K. K. A. (2024). The Role of Aflibercept (Eylea) Intravitreal Injection in Treatment of Resistant or CNV Complicated CSR (Central Serous Retinopathy). South Eastern European Journal of Public Health, 685–690. https://doi.org/10.70135/seejph.vi.1504

Issue

Special Volume XXIII No.3 2024: The Efficiency, Accuracy, and Distribution of Healthcare Services

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.